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There is currently no consensus regarding preferred clinical outcome measures following image-guided tumor ablation or clear
definitions of oncologic end points. This consensus document proposes standardized definitions for a broad range of oncologic outcome measures with recommendations on how to uniformly document, analyze, and report outcomes. The initiative was coordinated by the Society of Interventional Oncology in collaboration with the Definition for the Assessment of Time-to-Event End Points
in Cancer Trials, or DATECAN, group. According to predefined criteria, based on experience with clinical trials, an international
panel of 62 experts convened. Recommendations were developed using the validated three-step modified Delphi consensus method.
Consensus was reached on when to assess outcomes per patient, per session, or per tumor; on starting and ending time and survival
time definitions; and on time-to-event end points. Although no consensus was reached on the preferred classification system to report complications, quality of life, and health economics issues, the panel did agree on using the most recent version of a validated
patient-reported outcome questionnaire. This article provides a framework of key opinion leader recommendations with the intent
to facilitate a clear interpretation of results and standardize worldwide communication. Widespread adoption will improve reproducibility, allow for accurate comparisons, and avoid misinterpretations in the field of interventional oncology research.
Published under a CC BY 4.0 license.
Online supplemental material is available for this article.

I

nterventional oncology is one of the fastest growing disciplines in clinical oncology and health care in general
(1). Its success is chiefly based on the minimally invasive
nature of the needle-, applicator-, and catheter-based image-guided procedures with lower complication rates, superior toxicity profiles, and often comparable or superior
mid- and long-term oncologic outcomes compared with
conventional treatment modalities such as surgical resection and systemic therapy (2–7). In clinical oncology, the
most objectively defined time-to-event end point to address clinical benefit is overall survival. However, a proliferation of pharmacologic treatments and dosing strategies has led to the use of surrogate end points to measure
interim treatment efficacy. Depending on the disease
setting, these include disease-free, recurrence-free, and
progression-free survival; local tumor progression-free
survival; organ-specific progression-free survival and distant progression-free survival; time to progression; time
to local (tumor) progression and time to organ-specific
progression; primary and assisted technique efficacy rates;
local tumor progression rate; and local control (8,9).
Throughout the interventional oncology literature,
these survival terms are loosely defined and are often
incorrectly used interchangeably. Accurate comparisons
between studies are hampered by the heterogeneous and
unclear reporting of oncologic outcome parameters,
which includes variability in the interpretation and use

of time-to-event end point terms and definitions of
starting and ending times.
In 2014, Ahmed et al (8) updated their keystone consensus report regarding the standardization of terminology
and reporting criteria, improving the precision of communications in this field. Although their article and the
supplement to the consensus document concisely mention
that (a) reporting of overall survival from start of ablation
and from time of diagnosis is required for all intermediateand long-term studies; (b) survival at specified time points
and median survival times should be reported, as well as
time to progression and progression-free survival; and
(c) local time to progression and local (tumor) progressionfree survival should be differentiated from organ-specific
time to progression and progression-free survival, clear definitions and recommendations on how to use and interpret
these parameters were not provided. Thus, in the field of
image-guided tumor ablation, standardization of terms is
required to facilitate effective communication.
The purpose of this modified Delphi consensus project was to provide standardized definitions of patient-,
session-, and tumor-related parameters and to offer recommendations on how to uniformly collect, analyze,
and report oncologic outcomes for patients treated with
image-guided tumor ablation. This project is a collaboration between the Society of Interventional Oncology
and the Definition for the Assessment of Time-to-Event
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Summary
A panel of experts reached consensus on recommendations on when
to assess oncologic outcomes per patient, per session, and per tumor;
definitions of starting and ending times; definitions of survival time;
and time-to-event end points.

Essentials
N

N

N

An expert panel reached consensus on (a) recommendations on
when to assess oncologic outcomes per patient, per session, and
per tumor; (b) definitions of starting and ending times; (c) definitions of survival time; and (d) time-to-event end points.
Clear definitions will ensure an objective and reliable interpretation of results, allow for an accurate comparison of outcomes,
avoid misinterpretations, and provide the necessary foundation for
scientific reproducibility among studies.
Adoption of the recommendations will facilitate and improve
worldwide communication of scientific advances in the field of
interventional oncology.

End Points in Cancer Trials Initiative, or DATECAN, group,
whose final intention is to obtain harmonized consensus definitions that advance intersociety communications (9).

Study Methodology
The initial methodology was developed and previously applied in four disease-specific projects, including pancreatic
cancer (10), sarcoma and gastrointestinal stromal tumor (11),
breast cancer (12), and renal cell cancer (13) initiatives. Institutional review board approval was not required as this study
does not involve human participants. This article should be
considered a supplement to the standardization of terminology reporting criteria recommended by Ahmed et al (8).
Coordinating Committee
The coordinating committee (Table E1 [online]) was composed of Society of Interventional Oncology research committee members (M.R.M., S.N.G., M.A., M.C.S., J.C., J.P.E.,
G. Nadolski, I.N.), one representative from the Definition for
the Assessment of Time-to-Event End Points in Cancer Trials Initiative (C.B.), one health economist (V.M.H.C.), two
epidemiologists (V.M.H.C., B.I.L.W.), one study coordinator
(R.S.P.), and one operations manager (T.G.). The coordinating
committee was responsible for the methodologic protocol and
conduct (M.R.M., R.S.P., S.N.G., M.A., M.C.S., J.C., J.P.E.,
G. Nadolski, I.N., C.B.), survey and questionnaires (all coordinating committee members), data collection and analysis
(M.R.M., R.S.P., S.N.G., M.A., C.B., V.M.H.C., B.I.L.W.),
and guideline and manuscript preparation (all coordinating
committee members).
Evaluating Committee
The coordinating committee reached out to at least one active
board member of the following international scientific groups or
organizations: Society of Interventional Oncology, Technology
Assessment Committee of the Society of Interventional Radiology, Standard of Practice Committee of the Cardiovascular and
Interventional Radiological Society of Europe, Interventional
Oncology Sans Frontières Expert Panel, and Asian Society of
2

Tumor Ablation. The board members were asked to provide us
with a list of key opinion leaders. All potential participants in
the evaluating committee (Table E2 [online]) were required to
confirm that they had at least 5 years of experience in the field
of clinical oncology research, published at least one article for a
given cancer site, and participated in at least three clinical oncology trials. After having confirmed these requirements in the
online questionnaire, all were asked if they could think of further
participants. A total of 62 key opinion leaders from Europe (n =
29), the United States (n = 25), and Asia (n = 8) working in 48
centers eventually joined the evaluating committee. Data on experts’ demographics, such as year of birth, current job position,
professional membership, country of residence, time (in years)
working in the field of interventional oncology, and familiarity
with oncologic outcomes metrics, were collected.
Literature Review and Questionnaire Construction
A PubMed literature search resulted in a list of short-, mid-,
and long-term oncologic outcome measures and time-toevent end points (Appendix E1 [online]). This list was used
by the coordinating committee to generate the first questionnaire. The formal consensus method involved the following
steps (Figure): (a) definition of problems, literature review,
and appointing the experts’ committees (by the coordinating
committee); (b) development of definitions and recommendations (by the coordinating committee); (c) a three-round
rating process and evaluation of responses (by the coordinating committee plus evaluating committee); (d) presentation
of results and final attempt to reach consensus during inperson teleconference; and (e) creation of a final report with
definitions plus recommendations.
Consensus Process
A modified Delphi consensus is a structured and validated
measurement instrument used for evaluation of expert opinion
on health and medical topics (14). It has been widely used to
establish consensus across a range of subject areas. The Delphi
process formalizes the degree of agreement among experts by
using a series of surveys that are iterated with feedback until
consensus is reached.
The guidelines were developed in four coordinating committee meetings (April 2019, June 2019, October 2019, and
January 2020). Two rating rounds and one in-person web-based
conference call were scheduled to develop the recommendations.
A total of three survey rounds, or fewer if consensus was reached
sooner, were prechosen as this enables adequate reflection on
group responses and is considered optimal to reach consensus.
The questionnaires were internet-based and sent by e-mail. All
panelists received a deadline for completing the survey and were
sent weekly reminders to encourage participation.
Before the first round, panelists agreed to review three a dditional
documents: (a) the standardization of terminology reporting criteria by Ahmed et al (8), (b) the list of relevant d
 efinitions as suggested by the coordinating committee (Appendix E1 [online]),
and (c) the key instructions for filling in the consensus document.
In round 1, statements were evaluated using a 9-point
Likert scale (where 1 = totally disagree and 9 = totally agree)
radiology.rsna.org n Radiology: Volume 000: Number 0—Month 2021
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The first-round answers were gathered and reported back to
the panelists in the second round, where panelists rated only
those items for which consensus had not been reached. Based
on the first-round dispersal of scores (minimum, maximum,
and median scores), each panelist was encouraged to reassess his
or her initial judgments. Finally, for items remaining without
consensus, a third round was organized. This in-person teleconference, led by a representative of the coordinating committee
(M.R.M.), involved members of the coordinating committee
and evaluating committee. The remaining items were discussed,
and a preliminary draft of the recommendations was composed
for validation by all panelists.

Results

Flowchart of study design. The formal Delphi consensus method consisted of five
steps: step 1, definition of problems, literature review, and appointing the experts’
committees (by the coordinating committee [CC]); step 2, development of definitions and recommendations (by the coordinating committee); step 3, three-round
rating process and evaluation of responses, including a final third round to reach
consensus during a webinar (by the coordinating committee and evaluating committee [EC]); step 4, presentation of recommendations and manuscript to the evaluating committee; and, step 5, creation of the final manuscript.

to produce stable findings in Delphi consensus projects (9).
For each statement, panelists were given a free-text response
option. Relevant items previously defined by Ahmed et al
(8) were presented, and panelists were asked whether the
items could use adjustments. Items with strong consensus
were locked and archived. Consensus was considered strong
if all responses to a certain item were between 7 and 9, allowing up to two outliers. Strong consensus for the remaining single-answer multiple choice questions was defined as
having reached at least 80% agreement among panelists.
Data were analyzed anonymously.
Radiology: Volume 000: Number 0—Month 2021 n radiology.rsna.org

The coordinating committee drafted a list of 62 key opinion leaders in the field of interventional oncology. Thirty-six of those 62
experts (58%) participated in the first round. All panelists are
board-certified interventional radiologists. The panelists had an
average of 20.9 years of experience (standard deviation, 7.7 years)
in the field of interventional radiology, 11.1 years of experience
(standard deviation, 7.7 years) in clinical trials serving as principal investigator, and 17.7 years of experience (standard deviation,
6.7 years) in clinical trials serving as collaborator. All panelists
were familiar with oncologic outcome measures in their practice:
78% (28 of 36 panelists) always use them and 22% (eight of 36
panelists) use them occasionally. Additional detailed information
regarding the panelists and their affiliated institutions is listed in
Tables E1 and E2 (online). The experts rated a total of 62 items. A
detailed comprehensive overview of the results, including all items
and the level of agreement, is shown in Figure E1 (online).
Response rates were 58% (36 of 62 panelists), 56% (24 of
43 panelists), and 54% (23 of 43 panelists) in rounds 1 (July
to October 2019), 2 (November 2019 to January 2020), and
3 (March 30, 2020), respectively. In round 1, consensus was
reached on 27 of the 60 items (45%). The remaining 33 items
were reiterated in the second round and two additional items,
which emerged in the first round, were added. After two rounds,
consensus was reached on 56 of the 62 items (90%). The remaining six items were discussed face-to-face in a videoconference (round 3; March 30, 2020). No consensus was reached
regarding the recommended validated classification system to
register complications, adverse events, quality of life, and health
economics–related issues, although the panelists did agree to recommend the following statement: To document complications,
adverse events, quality of life, and health economics–related issues, one should use and report the most recent version of a validated patient-reported outcome questionnaire.
In the first round, several panelists requested clarification regarding the use of the terms to document, to analyze, and to report.
Accordingly, for future rounds the steering committee reached
consensus regarding the following definitions: (a) to document
means to collect and store patient-, procedure-, or tumor-related
parameters in a centralized (preferably electronic, secure, and
anonymized) study or registry database; (b) to analyze means
to calculate, assess, and interpret congregated data derived from
the documented patient-, procedure-, and tumor-related parameters; and (c) to report means to disclose the analyzed patient-,
3
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procedure-, and tumor-related parameters in relation to the
study outcomes with the intent to publish one’s findings.
The consensus items were translated into the following recommendations by the coordinating committee to which the
evaluating committee anonymously agreed.

Recommendations
Addressing Outcomes per Patient, per Procedure, or per
Tumor
When assessing time-to-event data in randomized controlled
trials, single-arm prospective studies, and/or retrospective comparative and noncomparative series, the following definitions
should be analyzed per patient and not on a per-tumor or perprocedure basis: overall survival, disease-specific overall survival,
disease-free survival, recurrence-free survival, progression-free
survival, and distant progression-free survival (Table E3 [online]). Parameters that address both procedure-related adverse
effects and direct costs should be addressed per procedure. This
includes short-terms complications, anesthesia techniques, hospital-stay characteristics, and laboratory tests that, for example,
assess organ function and the presence or absence of infectious
complications. Technical success should be addressed per tumor
and per procedure and not per patient. The term session can be
used as a synonym for procedure. To assess the local efficacy of
an ablative intervention, regardless of the oncologic outcome(s),
one should address and report the following parameters per
patient and per tumor: local tumor progression-free survival,
time to local (tumor) progression, freedom from local or organspecific recurrence, primary and secondary or assisted technique
efficacy, residual disease, local progression, recurrence rates, and
local control. Multiple index tumors (eg, multiple colorectal
metastases or multifocal hepatocellular carcinoma) within one
unique patient cannot be regarded as independent as these tumors are potentially correlated and hence study outcomes hypothetically interlinked. When using standard survival estimates
(Kaplan-Meier or cumulative incidence functions), in cases with
multiple index tumors in one patient, the dependency of partially correlated or clustered data is ignored and this potential
limitation should be reported and stated in the discussion.
Starting and Ending Time Definitions
When assessing time-to-event data in randomized controlled trials, patients who did not receive the allocated treatment should
be included in the intention-to-treat analysis. According to
the intention-to-treat analysis, the starting time should be the
date of randomization. In trials where all patients, regardless of
the eventual randomization arm, are treated with induction or
neoadjuvant therapy, randomization should be performed after
completion of the neoadjuvant therapy. In addition, adding a
per-protocol analysis should be considered, including only patients who actually received the allocated treatment, especially if
a potential bias due to exclusion of patients exists. According to
the specific per-protocol analysis, when assessing time-to-event
data in randomized controlled trials, the starting time should
also be the date of randomization. In addition, it should be considered to add data regarding the time from the intervention,
4

especially when the period between randomization and eventual
intervention is long or heterogeneous or if a large number of
crossovers and/or patient dropouts exist.
For single-arm prospective studies and for retrospective comparative and noncomparative series, the starting time should be
the date of the first intervention even if the therapy may require
completion procedures (eg, completion ablation for insufficient
margins). In case of sequential procedures (eg, a preplanned twostage ablation followed by transarterial chemoembolization), the
starting time should be the date of the first intervention.
When focusing on single-arm prospective series, where patients receive strict and homogeneous neoadjuvant or induction
chemotherapy and/or radiation therapy regimens, one should
document the time from (a) the date of detection of disease (diagnosis), (b) the date of the start of neoadjuvant or induction
therapy, and (c) the date of the first interventional procedure.
If the risk of including a certain referral bias, lead-time bias,
or immortality-time bias is present, then one should report timeto-event data both from the date of diagnosis and from the date
of the start of the intervention.
To assess mid- to long-term outcomes following a given interventional procedure, one should document (a) the date of unequivocal presence of the event and (b) the date of an alternative
event that excludes or alters the probability for a future event
to occur (competing risk). During follow-up after a given interventional procedure, one should separately document (a) the
date of the last contact moment (eg, laboratory tests, phone calls,
consultations) that reliably confirms or excludes the presence of
a given event, (b) the date of the last cross-sectional imaging or
surrogate test that reliably confirms or excludes the presence of
the event, and (c) (non)physical contact moments (eg, nontumor-specific laboratory tests, phone calls, consultations) that
reliably exclude death, but not the presence or absence of disease.
Survival Time Definitions
If the patient’s likelihood of dying from causes other than the
disease being studied is substantial (eg, as with elderly patients or
those with early-stage disease with a good prognosis), one should
document and report both overall survival and disease-specific
overall survival. In the statistical analysis, death due to causes
other than the disease being studied should be considered a competing risk for the disease-specific survival analysis.
For early disease stages, when the intervention is likely curative (eg, ablation of small renal tumors), one should use recurrence-free survival. For intermediate disease stages, when the
intervention is considered potentially curative (eg, ablation of
colorectal liver metastases), one should use disease-free survival.
For advanced disease stages, when the intervention is considered
palliative, one should use progression-free survival.
Time to progression is defined as the time between the starting time and any disease recurrence (local, regional, or distant).
Distant progression-free survival is defined as the time between
the starting time and distant tumor progression, but not local
or regional progression. Local tumor progression-free survival
is defined as the time between the starting time and local tumor progression per tumor treated (per-tumor analysis) or per
patient treated (per-patient analysis). Time-to-local (tumor)
radiology.rsna.org n Radiology: Volume 000: Number 0—Month 2021
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progression is defined as the time between the starting time
and local tumor progression per tumor treated, resulting in a
horizontally flipped survival curve (1 2 local tumor progression-free survival).
Death due to any cause without documented signs of local,
regional, or distant disease progression should be considered a
competing risk.
Time-to-Event Outcome Definitions and Data Censoring
To calculate the survival probability, one should use the KaplanMeier survival estimate method, including the number of events
and the numbers at risk at each evaluation time point. Cumulative incidence function curves are preferred or should be added
to the Kaplan-Meier estimates if the number of competing risks
in a certain (sub)group is substantial, showing the cumulative
failure rates over time due to a particular cause. With respect
to data censoring, one should report the type of data censoring (right-, left-, or interval-censored observations). The date of
cross-sectional imaging or any other technique that unequivocally demonstrates a certain event should be considered the date
of the event (left-censored data). Both for interim and final analyses, the date of assessment should be predefined either at a fixed
point in time after inclusion of a certain number of individuals
or after reaching a certain number of events. Any individuals
remaining event-free and at risk should be right censored. Interval-censored observations, where a virtual halftime date between
two cross-sectional imaging examinations is considered as the
actuarial date of the event, should be avoided.
Eligibility
In prospective randomized and nonrandomized studies, the
number of eligible patients (who fulfill the inclusion criteria
and who do not meet the criteria for exclusion) should be documented and reported, as well as the number of eligible patients
who eventually do not participate. If possible, the reason for
nonparticipation (eg, refusal or failure to meet the inclusion and
exclusion criteria during work-up and/or during neoadjuvant or
induction therapy) before formal recruitment (inclusion) should
be documented and reported.
Recruited (included) patients who signed informed consent are considered active study participants during the predefined time they are “within the study.” Active study participants who, for any reason (patient’s wish to end study
participation or loss to follow-up), fail to continue participation in the period predefined as “within the study” should
be considered study dropouts, regardless of whether they
dropped out before or after randomization.
If active study participants refuse to undergo the allocated
treatment arm, then the patient undoes their trial enrollment. To eliminate any undesired impact on study-related
outcomes, the investigators should formally end patients’ active participation before they receive any alternative therapy.
Patients who cross over from their allocated treatment arm
to another study treatment arm, but who remain “within the
study,” should be regarded as crossover patients. The number
of patients who cross over to another treatment arm should
always be minimized.
Radiology: Volume 000: Number 0—Month 2021 n radiology.rsna.org

Technical Success, Technique Efficacy, Local Control, and
Ablation Confirmation
Technical success addresses whether the tumor was treated according to protocol and covered completely by the ablation
zone, if possible by using ablation confirmation techniques (see
explanation below). One should document and report the technical success rates. Technique efficacy refers to a prospectively
defined point in time when complete ablation of macroscopic
tumor was achieved, as evidenced by imaging follow-up or any
alternative technique (ie, biopsy or serologic criteria). If a patient
died due to any cause before that point in time, then the event
should be analyzed and reported as a competing risk. Primary
efficacy rate refers to the percentage of target tumors successfully
eradicated following the initial ablation, whereas secondary or
assisted technique efficacy rate refers to the percentage of target
tumors eventually eradicated, including with repeat ablations,
using the ablative method being studied. Local control is equivalent to assisted technique efficacy, with the exception that repeat
treatments using alternative methods (other ablative methods,
radiation therapy, or surgical excision) are allowed. Residual
unablated tumor refers to the presence of residual viable tumor
at the ablative margin at initial follow-up imaging, whereas local
tumor progression refers to reappearing viable tumor provided
that at least one contrast-enhanced follow-up study did not reveal residual viable tumor at the ablative margin.
Ablation confirmation refers to postprocedural imaging, or
any alternative technique, that is implemented with the intent
to allow for additional overlapping (completion) procedures
either within the same procedure or in a complementary completion session in the days or weeks hereafter. For percutaneous ablations, one should attempt to document and report the
minimum tumor-free margin. For CT-guided ablations, rigid
or nonrigid image fusion and registration should be performed
to confirm complete ablations, including circumferential safety
margins of treated peri-ablational tissue (8,15,16). One should
attempt to report the method of assessment of complete tumor
coverage and safety margins (eg, image fusion software) as close
to the time of ablation as possible, ideally immediately, or at least
within 24 hours after ablation.
Complications, Adverse Events, Quality of Life, and Health
Economics–related Outcomes
Complications, defined as any unexpected departure from a
(post)procedural course, and adverse events, defined as any
actual or potential injury related to a procedure, should be
documented and reported, citing the most recent version of
the used validated classification system so that they can be
categorized consistently according to severity, time of occurrence (eg, intraprocedural, postprocedural, or late), and likelihood of the event being related to the procedure. Although not
meant to represent an exclusive list, the following classification
systems are used to report complications and adverse events:
(a) Common Terminology Criteria for Adverse Events standards,
(b) Clavien-Dindo classification, (c) Society of Interventional Radiology classification, and (d) Cardiovascular and Interventional
Radiological Society of Europe Quality Assurance Document and
Standards for Classification of Complications (17–20). In accor5
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dance with the previous standardization of terminology consensus
document by Ahmed et al (8), pain should be reported using the
most recent version of the Common Terminology Criteria for Adverse Events of the National Cancer Institute.
Quality of life should be stratified according to disease stage
and patient’s functional status. One should document and specifically cite the most recent version of the validated classification system used. Quality of life should be assessed both before (baseline)
and after treatment, regardless of disease progression. Although
not meant to represent an exclusive list, the following standardized
questionnaires have been issued for assessing the quality of life:
(a) European Organization for Research and Treatment of Cancer,
(b) Functional Assessment of Chronic Illness Therapy or Cancer
Therapy, (c) World Health Organization Quality of Life scale
(WHOQOL-BREF), (d) Health Utilities Index, (e) Short Form
Health Surveys (SF-36, SF-12), (f) Nottingham Health Profile,
(g) Quality of Well-Being Scale, and (h) Consumer Assessment
of Healthcare Providers and Systems. Irrespective of the chosen
method, one should always attempt to use general measures; cancer-, treatment-, and symptom-specific questionnaires; and non–
cancer-specific (satisfaction) questionnaires.
For health economics–related outcomes, both a cost-effectiveness analysis and a comparative-effectiveness analysis are essential
for defining the position of tumor ablation in relation to its alternatives. Health economics–related outcomes should be documented
and reported, specifically citing the most recent version of a validated classification system used. Although not meant to represent
an exclusive list, standardized questionnaires that can be used include the generic EuroQoL Group (Rotterdam, the Netherlands)
forms for the assessment of quality-adjusted life years (EQ-5D;
EuroQol Group) and the Productivity and Disease Questionnaire,
or PRODISQ, for the assessment of cost-effectiveness.

Discussion
Over the past 2 decades, image-guided thermal and nonthermal
tumor ablation techniques have become indispensable therapeutic options for a variety of cancer types. For certain smaller-size
malignant tumors (eg, hepatocellular carcinoma, colorectal and
other liver and lung metastases, renal cell carcinoma, prostate
cancer, and neuroendocrine tumors), international guidelines
have already adopted thermal ablation as a first-line treatment
option (21–23). The continuing emergence of novel treatment
options and growing demand for minimally invasive imageguided tumor ablation techniques have raised the need for evidence-based interventional oncology, and with that comes the
need for clear documentation of oncologic outcome parameters.
The response rates in our study were 58%, 56%, and 54%
in rounds 1, 2, and 3, respectively. After three rounds, consensus was reached for all items but three (95%; 59 of 62 items).
Consensus was not reached for the preferred validated classification system to document, analyze, and report complications
and adverse events, quality of life, and health economics–related issues. Nonetheless, the panelists unanimously agreed on
the statement that “complications and adverse events, quality of
life, and health economics–related issues should be documented
and reported specifically citing the most recent version of the
validated classification system used.” Review of the literature and
6

discussions within the committees made it clear that outcome
assessment in interventional oncology can be challenging. To
date, neither a specific outcome nor a specific outcome measure
is a widely accepted standard tool in interventional oncology.
The disproportionate interest in the local effectiveness of a certain ablative technique and the complexity of correctly analyzing
treatment methods that can be repeated and that can be used to
treat m
 ultiple index tumors in a single individual can explain
this. However, it does not relieve treating physicians of their duty
to provide hard and unequivocal evidence that our treatments
prolong survival, improve quality of life, or reduce costs.
These guidelines for the definition of time-to-event end points
have been developed as an in-depth supplement to the more
concise standardization of terminology and reporting criteria in
image-guided tumor ablation published by Ahmed and colleagues
(8). The participation of independent epidemiologists and members of the Definition for the Assessment of Time-to-Event End
Points in Cancer Trials initiative study group and the large number
of international key opinion leaders from various institutions in
the expert panel, as well as the relatively high response rates for
all survey rounds, strengthen our methodology and indicate its
importance. As stated by the Centre for Evidence-based Medicine,
Delphi consensus studies are considered level 5 evidence (24). As
an anonymous technique, it prevents expert participants from
conforming to the opinion of others (25). Depending on the participant selection tools, the number of rounds and what to do in
which round, the specific cutoff values applied, and whether to
discuss with the experts has led to several variants of the original
Delphi method. The coordinating committee chose to use the
well-documented three-step modified Delphi consensus method
as proposed by Jones and Hunter (14), which is also used in the
development of various national clinical guidelines.
One potential drawback of our study was the relative homogeneity of the academic and professional background of
the panelists (all interventional radiologists). This may impair
the generalizability and validity of the recommendations made
herein. Nonetheless, image-guided tumor ablation is most often
performed by interventional radiologists, and the responsibility
to attend multidisciplinary tumor boards, to have a thorough
understanding of the guidelines and available evidence, to establish periprocedural care, and to provide robust evidence for
new oncologic interventions has previously been emphasized
by many, thus minimizing this limitation. General limitations
of the Delphi consensus method are the lack of guidance and
agreed standards on how to select participants and the fact that
it is time-consuming and laborious for participants, which explains why it is vulnerable to dropouts. Participants might also
drop out due to the long temporal commitment, distraction between rounds, or disappointment with the process.
This study provides a framework of key opinion leader
recommendations regarding patient-, procedure-, and tumorrelated definitions, starting and ending time definitions, survival time definitions, time-to-event end points, and patientreported outcome measures. Clear definitions will provide the
necessary foundation for scientific reproducibility between
studies as they will ensure an objective and reliable interpretation of results, allow for accurate comparison of outcomes, and
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avoid misinterpretations. We encourage all of our colleagues
to adopt the recommendations outlined in this proposal to facilitate worldwide communication of scientific advances in the
field of interventional oncology.
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